Loading organizations...
Loading organizations...
Cell and gene therapy for autoimmune diseases through gene editing.
RheumaGen has raised $15.0M across 1 funding round.
RheumaGen has raised $15.0M in total across 1 funding round.
RheumaGen has raised $15.0M in total across 1 funding round.
RheumaGen's investors include Tassos Konstantinou, William Taylor Nominees.
RheumaGen has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series A in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 9, 2025 | $15.0M Series A | Tassos Konstantinou, William Taylor Nominees |